Swiss National Bank increased its holdings in Masimo Co. (NASDAQ:MASI) by 2.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 94,000 shares of the medical equipment provider’s stock after acquiring an additional 2,300 shares during the quarter. Swiss National Bank owned approximately 0.18% of Masimo worth $13,989,000 at the end of the most recent quarter.
Other institutional investors have also made changes to their positions in the company. Financial Gravity Wealth Inc. acquired a new position in Masimo in the 2nd quarter valued at $31,000. FinTrust Capital Advisors LLC acquired a new position in Masimo in the 1st quarter valued at $61,000. NEXT Financial Group Inc increased its stake in Masimo by 172.0% in the 2nd quarter. NEXT Financial Group Inc now owns 544 shares of the medical equipment provider’s stock valued at $81,000 after buying an additional 344 shares during the period. Penserra Capital Management LLC acquired a new position in Masimo in the 1st quarter valued at $92,000. Finally, Advisory Services Network LLC increased its stake in Masimo by 2,062.5% in the 1st quarter. Advisory Services Network LLC now owns 865 shares of the medical equipment provider’s stock valued at $120,000 after buying an additional 825 shares during the period. 82.91% of the stock is currently owned by institutional investors and hedge funds.
In related news, EVP Anand Sampath sold 30,000 shares of the business’s stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $142.39, for a total value of $4,271,700.00. Following the sale, the executive vice president now directly owns 27,518 shares in the company, valued at approximately $3,918,288.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, COO Bilal Muhsin sold 10,000 shares of the business’s stock in a transaction dated Wednesday, June 5th. The stock was sold at an average price of $135.00, for a total transaction of $1,350,000.00. Following the completion of the sale, the chief operating officer now owns 10,000 shares in the company, valued at $1,350,000. The disclosure for this sale can be found here. Insiders have sold a total of 258,738 shares of company stock worth $38,858,247 over the last 90 days. Insiders own 11.50% of the company’s stock.
Masimo (NASDAQ:MASI) last issued its earnings results on Wednesday, July 31st. The medical equipment provider reported $0.76 EPS for the quarter, topping the consensus estimate of $0.73 by $0.03. The company had revenue of $229.60 million for the quarter, compared to analyst estimates of $222.46 million. Masimo had a net margin of 22.15% and a return on equity of 17.82%. The business’s revenue was up 8.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.73 EPS. As a group, equities research analysts forecast that Masimo Co. will post 3.15 earnings per share for the current year.
Several equities analysts have issued reports on the stock. Zacks Investment Research raised shares of Masimo from a “hold” rating to a “buy” rating and set a $153.00 price objective on the stock in a research note on Wednesday, May 8th. Needham & Company LLC reissued a “buy” rating and issued a $158.00 price objective (up from $155.00) on shares of Masimo in a research note on Tuesday, May 7th. Stifel Nicolaus boosted their target price on shares of Masimo from $165.00 to $170.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st. UBS Group boosted their target price on shares of Masimo from $172.00 to $180.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st. Finally, BTIG Research restated a “hold” rating on shares of Masimo in a research report on Thursday, August 1st. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $159.25.
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
Featured Article: Buy-Side Analysts
Want to see what other hedge funds are holding MASI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Masimo Co. (NASDAQ:MASI).
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.